Some investors asked on the investor interaction platform: is there any difference between the technical route of covid-19 specific drug and Junshi, and how are the experimental data compared?
Shan Dong Kexing Bioproducts Co.Ltd(688136) ( Shan Dong Kexing Bioproducts Co.Ltd(688136) . SH) said on the investor interaction platform on April 7 that the oral small molecule covid-19 virus therapeutic drug developed by the company is the same as Shanghai Junshi Biosciences Co.Ltd(688180) ‘s vv116 target (RdRp). According to the laboratory data, shen26 has a significant effect on the antiviral activity of covid-19 virus delta strain and Omicron strain in vitro.
